SCHEMBL262959

SCHEMBL262959

CCOC(=O)c1cn(COCC[Si](C)(C)C)nc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.38
TEAD2 Q15562 1/20 0.38
ALDH1A1 P00352 6/20 0.38
KDM4E B2RXH2 5/20 0.38
MAPT P10636 3/20 0.38
HSD17B10 Q99714 1/20 0.38
DGAT1 O75907 1/20 0.37
HPGD P15428 1/20 0.37
DCTPP1 Q9H773 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 2/20 0.36
BAZ2B Q9UIF8 1/20 0.35
BAZ2A Q9UIF9 1/20 0.35
MEN1 O00255 1/20 0.35
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
CSNK1D P48730 1/20 0.34
MAPK1 P28482 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20028126 0.88 CA12 (0.39) TSHRTEAD2ALDH1A1KDM4EMAPT
SCHEMBL30942930 0.87 ALDH1A1 (0.39) TSHRTEAD2ALDH1A1KDM4EMAPT
SCHEMBL27179286 0.87 TEAD2 (0.41) TSHRTEAD2ALDH1A1KDM4EMAPT
SCHEMBL2703610 0.87 TEAD2 (0.36) TSHRTEAD2ALDH1A1KDM4EMAPT
SCHEMBL264496 0.85 KLKB1 (0.37) ALDH1A1KDM4EDGAT1HPGDNPC1
SCHEMBL25405049 0.84 GRM2 (0.44) ALDH1A1KDM4EHSD17B10DGAT1HPGD
SCHEMBL20531567 0.84 KDM4E (0.41) TEAD2ALDH1A1KDM4EMAPTHSD17B10
SCHEMBL18131250 0.83 MAPT (0.39) TEAD2ALDH1A1MAPTDGAT1HPGD
SCHEMBL28734609 0.83 TEAD2 (0.34) TSHRTEAD2ALDH1A1KDM4EMAPT
SCHEMBL26958767 0.83 DGAT1 (0.41) TSHRTEAD2ALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2024-03-28 US disclosed
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP disclosed
US-8134007-B2 Pyridine derivatives PFIZER INC. (US) 2012-03-13 US disclosed
US-8134007-B2 Pyridine derivatives PFIZER INC. (US) 2012-03-13 US disclosed
EP-2183241-A2 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS Pfizer Limited (GB) 2010-05-12 EP disclosed
US-20090048306-A1 PYRIDINE DERIVATIVES PFIZER, INC. (US) 2009-02-19 US disclosed
US-20090048306-A1 PYRIDINE DERIVATIVES PFIZER, INC. (US) 2009-02-19 US disclosed
WO-2008135826-A2 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LIMITED (GB) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS KCNA1, KCNB1, KCNB2 TSHR 1321/4885TEAD2 2488/4885ALDH1A1 1731/4885
US-20090048306-A1 PYRIDINE DERIVATIVES SDHA, P2RX4, P2RX3 TSHR 3678/4885TEAD2 1568/4885ALDH1A1 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.